



ISN FRONTIERS MEETINGS

**KIDNEY DISEASE &
CARDIOVASCULAR DISEASE**
FEBRUARY 22-25, 2018
TOKYO, JAPAN

PROGRAM BOOK & BOOK OF ABSTRACTS

Advancing Worldwide Kidney Health



Japanese Society of
Nephrology



Japanese Society for
Dialysis Therapy



Program



Program at a glance

Thursday

Plenary lecture 1:

Chairs: Adeera Levin, Canada and Naoki Kashihara, Japan

Room 3 (South Tower 4F Ohgi)

16:15 - 17:10 Molecular mechanism of CRISPR-Cas and structure-based development of genome editing tool towards medical applications
Osamu Nureki, Japan

Keynote lecture 1:

Chairs: Stuart Shankland, USA and Masaomi Nangaku, Japan

Room 3 (South Tower 4F Ohgi)

17:10 - 17:45 New strategies for the prevention of cardiovascular and renal diseases in type 2 diabetes
Takashi Kadowaki, Japan

Symposium 1:

Chairs: Kent Doi, Japan and Jimmy Teo Boon Wee, Singapore

Room 3 (South Tower 4F Ohgi)

AKI and CVD

18:00 - 18:20 Heart-kidney interaction: Cardiorenal syndrome in critical care
Yung-Chang Chen, Taiwan

18:20 - 18:40 Acute kidney injury (AKI) in cancer chemotherapy
Yuichi Ando, Japan

18:40 - 19:00 AKI and maladaptive repair: From the laboratory to the clinic
Joseph V. Bonventre, USA

19:00 - 19:20 Influence of neuroimmune axis on AKI
Tsuyoshi Inoue, USA

Joint with the JSN / JSNP

Thursday, February 22



Friday

Morning seminar 1:

Room 2 (South Tower 4F Nishiki)
Chair: Yoshihiko Kanno, Japan

- 8:00 - 8:55 Diagnosis and treatment of atypical hemolytic uremic syndrome (aHUS)
Shoichi Maruyama, Japan
- Co-sponsored by Alexion

Symposium 2:

Room 1 (South Tower 5F Eminence Hall)
Chairs: Yoshihiko Saito, Japan and Ginova Nainggolan, Indonesia

Cardio-renal syndrome

- 9:10 - 9:30 Cardiovascular disease and multimorbidity in older people with chronic kidney disease
Marcello Tonelli, Canada
- 9:30 - 9:50 Inflammaging and vascular calcification in chronic kidney disease
Catherine M. Shanahan, UK
- 9:50 - 10:10 A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation.
Katsuhito Fujiu, Japan
- 10:10 - 10:30 Endothelial cell dysfunction in CKD and CVD
Minoru Satoh, Japan

Joint with the JSN / JCS

Young investigator network session:

Room 2 (South Tower 4F Nishiki)
Chairs: Carol Pollock, Australia and Kenichiro Kitamura, Japan

- 9:10 - 9:20 miR-146a targeting the splenic macrophages prevents sepsis-induced acute kidney injury
Yoshio Funahashi, Japan
- 9:20 - 9:30 Magnesium and the risk of fatal myocardial infarction in patients undergoing hemodialysis
Yusuke Sakaguchi, Japan
- 9:30 - 9:40 The transcription factor MafB is essential for the maintenance of podocytes.
Toshiaki Usui, Japan
- 9:40 - 9:50 Ejection fraction as a predictor of survival among elderly patients with ESRD initiating maintenance hemodialysis
Matthew R D'Costa, USA



- 9:50 - 10:00 Neural transcription factor Pou4f1 is essential for macrophage-myofibroblast transition driven kidney fibrosis
Patrick Ming-Kuen Tang, Hong Kong
- 10:00 - 10:10 The association of RAAS blockade and the progression of residual kidney function decline: A nation-wide prospective cohort study
Kyung Don Yoo, Korea
- 10:10 - 10:20 Rituximab improves cytoskeletal remodeling of podocytes induced by interleukin-13.
Yuno Takahashi, Japan

Symposium 3:

Room 1 (South Tower 5F Eminence Hall)

Chairs: Naotake Tsuboi, Japan and Ravi Thadhani, USA

Phosphate toxicity and CVD

- 10:50 - 11:10 Phosphate and cardiovascular calcification
Ziad A. Massy, France
- 11:10 - 11:30 Phosphate binders and outcome
Hirotaaka Komaba, Japan
- 11:30 - 11:50 Which is bad: FGF23 or phosphate
Tamara Isakova, USA
- 11:50 - 12:10 Magnesium as a suppressor of phosphate toxicity
Yusuke Sakaguchi, Japan

Co-sponsored by Kissei Pharmaceutical

Symposium 4:

Room 2 (South Tower 4F Nishiki)

Chairs: Kouichi Tamura, Japan and Chin-Wei Yang, Taiwan

CKD and CVD

- 10:50 - 11:10 Mineral metabolism and cardiovascular disease in CKD
John Cunningham, UK
- 11:10 - 11:30 Cardiovascular risk prediction in CKD patients
Kunihiro Matsushita, USA
- 11:30 - 11:50 Pathophysiology of cerebro-cardio-renal continuum in patients with chronic kidney disease
Naoki Nakagawa, Japan
- 11:50 - 12:10 Vascular calcification and vascular stiffness in CKD
Paweena Susantitaphong, Thailand

Co-sponsored by DAIICHI SANKYO CO., LTD.



Luncheon seminar 1:

Room 1 (South Tower 5F Eminence Hall)

Chair: Ryo Okazaki, Japan

12:25 - 13:20 Reno-skeletal syndrome
Junichiro James Kazama, Japan

Co-sponsored by Astellas Pharma Inc.

Luncheon seminar 2:

Room 2 (South Tower 4F Nishiki)

Chair: Hirokazu Okada, Japan

12:25 - 13:20 Iron in the era of HIF stabilizers
Takayuki Hamano, Japan

Co-sponsored by TORII PHARMACEUTICAL CO., LTD.

Plenary lecture 2:

Room 1 (South Tower 5F Eminence Hall)

Chairs: Carol Pollock, Australia and Hidetomo Nakamoto, Japan

13:30 - 14:25 Digital health solutions & new payment models: The transforming of
chronic care
Lisa Pettigrew, USA

Symposium 5:

Room 1 (South Tower 5F Eminence Hall)

Chairs: Jun Wada, Japan and Sydney C.W. Tang, Hong Kong

DKD and CVD: Clinical

14:40 - 15:00 Combating DKD: From pathogenesis to treatment
Keizo Kanasaki, Japan

15:00 - 15:30 Clinical impact of novel anti-diabetic agents in DKD
Per-Henrik Groop, Finland

15:30 - 16:00 From bench to bedside in DKD
Mark Cooper, Australia

16:00 - 16:30 Clinical and genetic approaches to DKD
Juliana Chan, Hong Kong

Co-sponsored by Boehringer Ingelheim GmbH Co., Ltd. / Eli Lilly KK.

Symposium 6:

Room 2 (South Tower 4F Nishiki)

Chairs: Joseph V. Bonventre, USA and Reiko Inagi, Japan

Hypoxia biology in kidney disease and CVD

14:40 - 15:00 Oxygen biology and the kidney
Kai-Uwe Eckardt, Germany

15:00 - 15:20 Renal oxygenation on cardiopulmonary bypass and risk of post-operative
acute kidney injury
Roger Evans, Australia



15:20 - 15:40 Novel treatment to activate HIF
Tetsuhiro Tanaka, Japan

15:40 - 16:00 Renal capillary flow and hypoxia in kidney injury
Daisuke Nakano, Japan

Joint with the JSN / JSDT

Evening seminar 1:

Room 1 (South Tower 5F Eminence Hall)

Chair: *Ichiei Narita, Japan*

16:40 - 17:35 Aldosterone, hypertension and the kidney: Recent advances
Shigeru Shibata, Japan
Co-sponsored by Mochida Pharmaceutical Co., LTD. / EA Pharma Co., Ltd.

Evening seminar 2:

Room 2 (South Tower 4F Nishiki)

Chair: *Tadao Akizawa, Japan*

16:40 - 17:35 Current status of chronic kidney disease in Korea; How to overcome the
unmet need in CKD
Yon Su Kim, Korea
Co-sponsored by KUREHA CORPORATION / Mitsubishi Tanabe Pharma Corporation



Saturday

Morning seminar 2:

Room 2 (South Tower 4F Nishiki)
Chair: Takashi Shigematsu, Japan

8:00 - 8:55 Application of AI/ICT technology to kidney disease management
Yoshitaka Isaka, Japan

Co-sponsored by Nikkiso

Symposium 7: Chairs: Kumiko Torisu, Japan and Kriengsak Vareesangthip, Thailand

Room 1 (South Tower 5F Eminence Hall)

DKD and CVD basic

9:10 - 9:30 Diabetic kidney disease: New targets for treatment
Katherine R. Tuttle, USA

9:30 - 9:50 New approaches to treatment of DKD
Robyn Langham, Australia

9:50 - 10:10 Inflammation in diabetic kidney disease
Sydney C.W. Tang, Hong Kong

10:10 - 10:30 Vaspin and proximal tubular cell injury in metabolic syndrome.
Atsuko Nakatsuka, Japan

Joint with the JSN / JDS

Symposium 8: Chairs: Matsuhiko Hayashi, Japan and Yugo Shibagaki, Japan

Room 2 (South Tower 4F Nishiki)

aHUS and systemic vascular injury

9:10 - 9:30 Transplantation and thrombotic microangiopathy (TMA)
Toby Coates, Australia

9:30 - 9:50 Update on STEC-HUS
Christine B. Sethna, USA

9:50 - 10:10 Atypical HUS in pediatric patients
Toshihiro Sawai, Japan

10:10 - 10:30 Atypical HUS in adult patients
Yoko Yoshida, Japan

Co-sponsored by Alexion

Saturday, February 24



Symposium 9:

Room 1 (South Tower 5F Eminence Hall)

Chairs: John Cunningham, UK and Tae Yamamoto, Japan

Dialysis and CVD: Clinical

- 10:45 - 11:05 Dialysis and CVD: Chinese cohort study
Xueqing Yu, China
- 11:05 - 11:25 Management of CKD-MBD in haemodialysis: Lessons from COSMOS
Jorge B. Cannata-Andía, Spain
- 11:25 - 11:45 CKD and CVD in Asia: Lessons from cohort studies and clinical trials
Vivekanand Jha, India
- 11:45 - 12:05 Clinical studies of cardiovascular interventions in PD patients
David Johnson, Australia

Co-sponsored by Kyowa Hakko Kirin Co., Ltd.

Symposium 10:

Room 2 (South Tower 4F Nishiki)

Chairs: Orson W. Moe, USA and Daisuke Nagata, Japan

CKD-MBD and CVD

- 10:45 - 11:05 Evidence for and against the link between MBD and CVD
Ravi Thadhani, USA
- 11:05 - 11:25 Calcimimetics and CVD
Takayuki Hamano, Japan
- 11:25 - 11:45 Vascular calcification
Cecilia Giachelli, USA
- 11:45 - 12:05 Hidden hypercalcemia
Yoshitsugu Obi, USA

Co-sponsored by ONO PHARMACEUTICAL CO., LTD.

Luncheon seminar 3:

Room 1 (South Tower 5F Eminence Hall)

Chairs: Ken Tsuchiya, Japan and Masafumi Fukagawa, Japan

- 12:20 - 12:35 Management of phosphorus load in CKD patients
Masafumi Fukagawa, Japan
- 12:35 - 13:15 Vascular calcification in chronic kidney disease: Different bricks in the wall?
Mario Cozzolino, Italy

Co-sponsored by Bayer Yakuhin, Ltd.

Saturday, February 24



Luncheon seminar 4:

Room 2 (South Tower 4F Nishiki)
Chair: Takao Masaki, Japan

- 12:20 - 13:15 Protein-energy wasting and frailty in chronic kidney disease
Joel D. Kopple, USA
Co-sponsored by Chugai Pharmaceutical CO., LTD.

Plenary lecture 3:

Room 1 (South Tower 5F Eminence Hall)
Chairs: Kai-Uwe Eckardt, Germany and Kosaku Nitta, Japan

- 13:25 - 14:20 Elucidation of human oxygen sensing pathways: Implications for nephrology
Peter J. Ratcliffe, UK

Keynote lecture 2:

Room 1 (South Tower 5F Eminence Hall)
Chairs: Motoko Yanagita, Japan and Vivekanand Jha, India

- 14:20 - 14:55 Cardiovascular trials and kidney disease
Vlado Perkovic, Australia

Symposium 11:

Room 1 (South Tower 5F Eminence Hall)
Chairs: Yon Su Kim, Korea and Xueqing Yu, China

Transplantation and CVD

- 15:00 - 15:20 Antibody mediated rejection
Toby Coates, Australia
- 15:20 - 15:40 Long-term renal allograft survival
Adrian Liew, Singapore
- 15:40 - 16:00 Cardiovascular disease after kidney transplantation
Philip Kam-Tao Li, Hong Kong
- 16:00 - 16:20 Marginal donor in living-donor kidney transplantation
Tadashi Sofue, Japan

Joint with the JSN / JSdT

Symposium 12:

Room 2 (South Tower 4F Nishiki)
Chairs: Chih-Kang Chiang, Taiwan and Motoshi Hattori, Japan

Pediatric nephrology and CVD

- 15:00 - 15:20 Clinical and genetic approaches and developing a novel treatment for alport syndrome
Kandai Nozu, Japan
- 15:20 - 15:40 Pathogenic mechanism of childhood idiopathic nephrotic syndrome
Yutaka Harita, Japan



15:40 - 16:00 Vitamin D in childhood CKD-MBD: Panacea or placebo?
Rukshana Shroff, UK

16:00 - 16:20 Cardiovascular risk factors in children with kidney diseases
Christine B. Sethna, USA

Joint with the JSN / JSPN (pediatric)

Evening seminar 3:

Room 1 (South Tower 5F Eminence Hall)

Chair: Takashi Yokoo, Japan

ADPKD update

16:35 - 17:00 Tolvaptan for ADPKD: The latest clinical evidence and Japan's post-launch experience
Saori Nishio, Japan

17:00 - 17:25 Modelling polycystic kidney disease using iPS cells
Kenji Osafune, Japan

Co-sponsored by Otsuka Pharmaceutical Co., Ltd.

Evening seminar 4:

Room 2 (South Tower 4F Nishiki)

Chair: Yukio Yuzawa, Japan

Recent advances in Fabry disease

16:35 - 17:00 Cardiac involvement and the role of enzyme replacement therapy in Japanese Fabry patients
Kenichi Hongo, Japan

17:00 - 17:30 Screening of Fabry nephropathy in CKD patients not on dialysis
Kei Fukami, Japan

Co-sponsored by Sumitomo Dainippon Pharma Co., Ltd.

Special lecture:

Room 1 (South Tower 5F Eminence Hall)

Chair: Akira Nishiyama, Japan

17:30 - 18:20 SGLT2 inhibitors and diabetic kidney disease: The nephrologist's point of view
Christoph Wanner, Germany

Co-sponsored by Boehringer Ingelheim GmbH Co., Ltd. / Eli Lilly KK.

Saturday, February 24



Sunday

Morning seminar 3:

Room 2 (South Tower 4F Nishiki)
Chair: Yusuke Suzuki, Japan

- 8:05 - 9:00 Real-world treatment pattern of Japanese chronic kidney disease patients: A multicenter cohort study
Daijo Inaguma, Japan
- Co-sponsored by Kyowa Hakko Kirin Co., Ltd.

Plenary lecture 4:

Room 1 (South Tower 5F Eminence Hall)
Chairs: David Harris, Australia and Seiichi Matsuo, Japan

- 9:05 - 10:00 KEAP1-NRF2 system regulating oxidative stress response
Masayuki Yamamoto, Japan

Round-table discussion:

Room 2 (South Tower 4F Nishiki)
Chairs: Shinya Kaname, Japan and Eri Muso, Japan

A multidisciplinary CKD team care and expectations for the certificated kidney disease educators

- 9:15 - 10:00 Discussants
Yoshinari Yasuda, Japan
Akiko Uchida, Japan
Yuichi Ishikawa, Japan
Yuzuru Ito, Japan
- * This session is organized for Japanese certified kidney disease educators and operated in Japanese.

Symposium 13:

Room 1 (South Tower 5F Eminence Hall)
Chairs: Yutaka Taketani, Japan and Hyeong-Cheon Park, Korea

Nutrition in kidney disease and CVD

- 10:10 - 10:30 Sarcopenia and arteriosclerosis in CKD
Akihiko Kato, Japan
- 10:30 - 10:50 Gastrointestinal phosphate handling
Hiroko Segawa, Japan
- 10:50 - 11:10 Dietary management: Last but not the least important cardio-kidney protection strategy in CKD
Angela Yee-Moon Wang, Hong Kong
- 11:10 - 11:30 Phosphotoxicity: Implications on the cardiovascular system and general health
Orson W. Moe, USA

Joint with the JSN / JSDT



Symposium 14:

Room 2 (South Tower 4F Nishiki)

Chair: Mitsue Nakamura, Japan

Specialization of nephrology nursing
and development of multi-occupation collaboration

10:10 - 11:30 The conventional activity contents which "Japan academy of nephrology nursing (JANN)" went for and future role.
Hisamitsu Sato, Japan

10:10 - 11:30 Current activities of the DLN
Noriko Koteda, Japan

Organized by JANN

Luncheon seminar 5:

Room 2 (South Tower 4F Nishiki)

Chair: Takashi Wada, Japan

12:35 - 13:30 Tubulo-glomerular communication and renal effects by SGLT2 inhibitors
in type 2 diabetes
Shu Wakino, Japan

Co-sponsored by Mitsubishi Tanabe Pharma Corporation

Sunday, February 25

Speaker biographies




Biographies

Yuichi Ando



Yuichi ANDO has been a professor of the Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan, since May 2012, making full contribution to medical care, professional education and research in cancer chemotherapy. Dr. Ando received M.D. from the Nagoya University School of Medicine in 1990. After completing his residency training in Internal Medicine at the Japanese Red Cross Nagoya First Hospital, Dr. Ando received a Ph.D in Medical Science from Nagoya University. During his Ph.D. program, Dr. Ando trained in molecular pharmacology at Hokkaido University, Sapporo, Japan. Dr. Ando completed his postdoctoral fellowships as a Research Fellow of Japan Society of the Promotion of Science, and as a visiting fellow of the National Cancer Institute, Bethesda, MD. His interests include cancer chemotherapy, clinical pharmacology and clinical trials of anticancer agents under development. Dr. Ando is the recipient of the 2004 Incitement Award of the Japanese Cancer Association.

Joseph V. Bonventre



Joseph V. Bonventre, MD, PhD holds appointments as the Samuel A. Levine Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at MIT. He is Chief of the Division of Renal Medicine of the Brigham and Women's Hospital (BWH) and also founding Chief of the Division of Engineering in Medicine at the BWH. His research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. Bonventre has authored more than 360 original publications and 150 invited chapters and reviews, has received two MERIT awards from the National Institutes of Diabetes and Digestive and Kidney Disorders (NIDDK), and his work has been cited more than 52,000 times with an h-index of 118. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. He currently serves on the Advisory Council of the NIDDK.

Dr. Bonventre is currently on the Council of the International Society of Nephrology. He is a founding member of the Board of Directors of the National Space Biology Research Institute and has served on the Board of Advisors of the Norwegian Institute for Science and Technology and Board of Advisors of the Dean of the Cornell University School of Engineering. He has served on many NIH, ASN and other funding agency Study Sections and is Editor of Seminars in Nephrology. He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology. In November 2017, the ASN established the Joseph V. Bonventre Career Development Grant in recognition of Dr. Bonventre's contributions to nephrology and devotion to training and supporting the next generation of nephrologists.

In addition to his BS with distinction in Engineering Physics from Cornell, Bonventre holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology in Norway.



Jorge B. Cannata-Andía



Positions: Full Professor of Medicine at the University of Oviedo (Spain). Head of the Bone and Mineral Research Unit at the Reina Sofia Research Institute of the Hospital Universitario Central de Asturias, President of the UEMS (European Union Medical Specialists) Renal Section and Boards, Past Chair of the Education Committee of the ERA-EDTA, Ex- President and Secretary-Treasurer (2002-2008) of the ERA-EDTA, Ex-Council Member of the International Society of Nephrology, Member of the Scientific Advisory Board of the International Osteoporosis Foundation and Honorary Member of eight European and American Nephrology Associations.

Prof. Jorge B. Cannata-Andía's research activities in bone metabolic disorders and vascular calcifications have attracted more than 55 research projects (39 as principal investigator), 38 research awards (five of them related to his work in the renal and bone fields). He contributed to medical literature with more than 400 originals, reviews, originals and book chapters.

Juliana Chan



Professor Chan is a clinician scientist committed to translating evidence to practice and developing novel solutions for unmet needs. In the early 1990s, motivated by the observation of the high prevalence of young-onset type 2 diabetes and renal disease, she set up the Hong Kong Diabetes Registry and multiple cohorts to define the epidemiology of diabetes in Chinese populations. These prospective cohorts have laid the foundation for an overarching program to use a multiomic approach to discover genetic variants of diabetes and its complications for personalized care. She is currently a member of an NIH funded Global Consortium to discover causal genes in type 2 diabetes in a multi-ethnic population.

Yung-Chang Chen



Yung-Chang Chen, MD, is a professor and chairman of Department of Medicine at Keelung Chang Gung Memorial Hospital in Taiwan. He graduated from Taipei Medical University School of Medicine. He trained in internal medicine at the Chang Gung Memorial Hospital Linkou Medical Center. He completed post-doctor research fellow training at University of Colorado Health Science Center in US (July 2002 to June 2004), researching acute kidney injury (AKI), liver cirrhosis with renal dysfunction and renal aquaporin water channels studies under the supervision of professor Schrier. His recent research activities include prognostic scoring systems in critical care and AKI biosignature for cardiorenal syndrome. Those projects are supported by grants from the Ministry of Science and Technology (Taiwan) and Chang Gung Memorial Hospital Research Program.



Toby Coates



Toby Coates is a full time clinician-scientist in the Central Northern Adelaide Renal and Transplantation Service at the Royal Adelaide Hospital and Renal Transplant Nephrologist, Clinical Professor in Medicine at the University of Adelaide. He has 125 peer-reviewed publications and has supervised 16 Honours and PhD students to completion within the University of Adelaide. He is a member of the Australian Renal Transplant Advisory Committee of the Transplantation Society of Australia and New Zealand. He has been the associate editor for Transplantation for Kidney International since 2011. In 2017 he was appointed as an international councilor by the International Society of Nephrology for the Custodians of the Declaration of Istanbul. He is the current President Elect of the Transplantation Society of Australia and New Zealand. His research interests are clinical kidney and pancreas islet transplantation.

Mark Cooper



Professor Mark Cooper AO is Head of the recently-formed (1 January 2017) Diabetes Department in the Central Clinical School at Monash University. He was formerly Chief Scientific Officer, Baker IDI Heart and Diabetes Institute, and maintains an active clinical practice at The Alfred as a senior endocrinologist. His research interests are in diabetes and its three major complications: kidney disease, heart disease and blindness. Diabetes is a serious public health issue and the dramatic rise of diabetes in the community is a major concern. The complications of diabetes include kidney disease, eye disease and vascular disease. Diabetes is a major risk factor for cardiovascular disease and the most common cause of kidney failure in the western world.

Mario Cozzolino



Mario Cozzolino, MD, PhD, FERA, FASN is an Associate Professor in Nephrology and Chair of Nephrology at School of Medicine, University of Milan, Italy. He is the Director of the Renal Division at San Paolo Hospital, Milan, Italy, and the Director of the Laboratory of Experimental Nephrology at the Department of Health Sciences, University of Milan, Italy. In 2013, he was recognized as the Distinguished Fellow of the European Renal Association. In 2017, he was recognized as Fellow of the American Society of Nephrology. From 1999 to 2002 he was a Research Assistant in the Vitamin D Laboratory, Renal Division, Department of Internal Medicine, School of Medicine, Washington University, St. Louis, MO-USA. Director: Eduardo Slatopolsky, MD. Today, he is the Chairman of the CKD-MBD Working Group of European Society of Nephrology (ERA-EDTA). He has organized several congresses and meetings in the area of mineral metabolism and renal disease. His areas of interest are the mechanisms of pathogenesis of secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification in CKD patients. Recently, he started to study the genetic polymorphism of proteins involved in the molecular mechanisms of vascular calcification in CKD. Finally, he is deeply involved in developing new treatments of secondary hyperparathyroidism and hyperphosphatemia in CKD patients. In the last 15 years, he has been involved as a principal investigator in 20 international clinical trials on the Treatment of Hyperphosphatemia and Secondary Hyperparathyroidism in CKD and ESRD Patients. In 2015, 2016, and 2017, based on Expertscape's objective, quantitative multi-factorial analysis of scientific publications covering the past 10 years, he became the first of the world's top experts in the field of hyperparathyroidism research and treatment.

He is author of 232 publications on peer-reviewed journals (Total Impact Factor 623; Citations 4669; H-Index 35; i-10 index 110). He also serves as Associate Editor for "*Plos One*", "*Clinical Kidney Journal*", "*Journal of Nephrology*", and "*Blood Purification*" and as Peer Reviewer for 30 medical journals.

John Cunningham



John Cunningham is Professor of Nephrology at University College London Medical School and The Royal Free Hospital and an Honorary Fellow of Trinity Hall, University of Cambridge. His early training was at Cambridge and Oxford Universities, with postgraduate training at The University of London and Washington University School of Medicine, St Louis, USA under the direction of Drs Louis V Avioli and Eduardo Slatopolsky.

He is a member of the consultant staff of The Royal Free Hospital, St Mary's Hospital, The Royal Brompton Hospital and King Edward 7ths Hospital for Officers, all in London. The bulk of his clinical work is in general nephrology, renal and metabolic medicine, hypertension, renal stone disease, acute and chronic kidney disease, renal transplantation and dialysis, metabolic bone disease (including osteoporosis, hyperparathyroidism, vitamin D deficiency, renal bone disease and the interfaces between CKD, the mineral bone disorder, and cardiovascular disease.) From 2005 to 2014 John Cunningham was Physician to HM The Queen and Head of The Medical Household.

Academically Professor Cunningham has contributed to the understanding of the effect of acidosis on the bioactivation of vitamin D and described and characterized hysteresis in the parathyroid response to calcium, indicating that parathyroid cells can sense both the direction of change and the absolute concentration of ECF calcium. He subsequently ran research programmes examining the following: control by structurally modified vitamin D metabolites at PTH synthesis and release; the synthesis and release of bone cytokines by osteoblast like cells and the regulation of these by vitamin D metabolites; the location and relevance of the calcium sensing receptor in bone cells; the influence of simulated uraemia on the release of cytokines by bone cells; the factors mediating bone loss following renal transplantation and preventative strategies; the factors that control parathyroid function *in vivo*, including new vitamin D metabolites and calcimimetic agents. Professor Cunningham's group has found that new structurally modified metabolites of vitamin D differ markedly in the way they influence the behaviour of both parathyroid cells and bone cells. His group also devised, conducted and published studies of the first effective prophylaxis against bone loss in the post transplant setting. Over the past decade his work has focussed increasingly on the links between disorders of mineral metabolism in CKD, and the accelerated cardiovascular disease experienced by CKD patients. On these and other subjects, Professor Cunningham frequently lectures nationally and internationally, as well as serving on international expert panels and working groups. He is a founding Co-chairman of the Nephrology At The Limits series held under the auspices of University College London, The University of Cape Town, and The Lancet.



Kai-Uwe Eckardt



Kai-Uwe Eckardt is Professor of Medicine and Head of the Department of Nephrology and Medical Intensive Care at the Charité in Berlin, Germany. Prior to taking this position in April 2017 he was Chair of Nephrology and Hypertension at the University of Erlangen-Nürnberg, where he also served as Vice Dean for Research and International Affairs.

Dr. Eckardt's major scientific interests lie in the molecular mechanisms and relevance of oxygen sensing and the development of acute and chronic renal injury. He is principal investigator of the German Chronic Kidney Disease (GCKD) study, the largest CKD cohort study worldwide. Dr. Eckardt has served in various capacities for international organizations, including terms as council member of the ERA-EDTA, councillor and executive councillor of the ISN, past-chair of the ISN Forefront Committee, congress secretary for the WCN 2003, program chair for WCN 2009 and 2017, founding executive committee member and past co-chair of KDIGO.

Roger Evans



Roger Evans is a member of the Cardiovascular Disease Program of the Biomedicine Discovery Institute and a Professor in the Department of Physiology, Monash University. Roger obtained his PhD in Pharmacology (Monash University, 1988). He subsequently moved to the Baker Institute and then to the University of Melbourne to study the neural mechanisms involved in the hemodynamic responses to hypovolemia. In 1992 he returned to the Baker Institute to study the role of the kidney in the development of hypertension. In 1997 he moved to Monash University as a Fellow of the National Health and Medical Research Council of Australia (1997-2010), before taking up a continuing faculty position in 2011. Roger's major interest is renal oxygenation and the role of hypoxia in kidney disease. Roger was Editor-in-Chief of *Clinical and Experimental Pharmacology and Physiology* (2006-2013) and is currently an Associate Editor of *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* (2013-). He has authored more than 240 scientific papers and book chapters.

Katsuhito Fujii



AMED (Japan Agency for Medical Research and Development)-PRIME Researcher, Tokyo, Japan 2017-Present

PRESTO (Precursory Research for Embryonic Science and Technology) Researcher, Japan Science and Technology Agency, Tokyo, Japan 2013-2017

Assistant Professor of Department of Ubiquitous Health Informatics, The University of Tokyo, Tokyo, Japan 2015-Present

Assistant Professor of Translational System Biology and Medicine Initiative, The University of Tokyo, Tokyo, Japan 2008-2015

Assistant Professor of Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan 2007-2008


Masafumi Fukagawa



Masafumi Fukagawa, MD, PhD received his MD in 1983 from University of Tokyo School of Medicine, Tokyo, Japan. Following subspecialty training and PhD program in Tokyo, he was Research Fellow at Vanderbilt University School of Medicine, TN (USA) until 1995.

From 2000 to 2009, Dr Fukagawa was Associate Professor and Director of the Division of Nephrology and Kidney Center at Kobe University School of Medicine, Kobe, Japan. Since 2009, he has moved to Tokai University School of Medicine, Isehara, Japan, as Professor of Medicine and the Director of Division of Nephrology, Endocrinology, and Metabolism. He is a member of KDIGO Work Group on CKD-MBD global guideline for the original version and for update. He also chaired the committee for the new version of Japanese clinical guideline on CKD-MBD by JSDT.

Kei Fukami



Awards:

18th Scientific Meeting of the International Society of Hypertension; The Young Investigator Travel Award 2000

1st Bayer Clinical Vascular Function Award 2000

Kurume University Science Award 2008

CKD Poster Award 2008

Education:

1993 Graduated at Kurume University School of Medicine
1993-1995 Department of Nephrology and Internal Medicine III, Kurume University School of Medicine—As clinical fellow—
1995-1997 Adult disease medical center of the city of Fukuoka—As clinical fellow—
1997-2004 Assistant professor at the Department of Nephrology and Internal Medicine III, Kurume University School of Medicine
2004-2006 Baker IDI Heart and Diabetes Institute NHMRC, Melbourne, Australia
2006-2011 Assistant professor at the Division of Nephrology, Department of Medicine, Kurume University School of Medicine
2011-2015 Associate professor at the Division of Nephrology, Department of Medicine, Kurume University School of Medicine
2012- Head of Dialysis Center at the Kurume University Hospital
2015- Professor of Medicine, Division of Nephrology, Department of Medicine, Kurume University School of Medicine



Cecilia Giachelli



Dr. Giachelli received a BS in Biochemistry from UC Davis and PhD in Pharmacology from the University of Washington, where she is currently Professor and Chair of Bioengineering, and Adjunct Professor of Pathology and Oral Health Sciences. Dr. Giachelli is internationally recognized for her work investigating the molecular mechanisms of ectopic calcification and extracellular matrix control of cell function. Her studies have led to the discovery of key inducers and inhibitors that contribute to ectopic calcification in the setting of chronic kidney disease, valve disease, atherosclerosis and medical devices. These discoveries are currently being translated to therapeutic strategies to block inappropriate calcification in disease and biomaterials development. Other key areas of research include control of inflammation and foreign body reaction, regenerative medicine, cell and tissue engineering. Dr. Giachelli is an elected fellow of the American Institute for Medical and Biological Engineering and the Washington State Academy of Sciences, and recipient of the American Heart Association Established Investigator Award, the Advances in Mineral Metabolism Investigator Award, and the American Society of Nephrology's Jack W. Coburn Lectureship.

Per-Henrik Groop




Professor Per-Henrik Groop, MD, DMSc, FRCPE graduated from the University of Helsinki in 1982. It was also where he defended his thesis on '*The relationship between GIP and beta-cell function in man*' in 1989. Following post-doctoral studies at Guy's Hospital, University of London, under Professor Giancarlo Viberti, Professor Groop returned to Helsinki as Consultant of Nephrology. He served as Professor of Nephrology (Chair) 2010-2015 and is currently Professor of Internal Medicine (Chair) at the University of Helsinki. He is also Chief Physician at the Abdominal Center of Nephrology, University of Helsinki and Helsinki University Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland. He is Adjunct Professor at the Department of Diabetes, Monash University, Melbourne, Australia.

Takayuki Hamano




Dr. Takayuki Hamano received his MD degree in 1998 from Osaka University, Japan and completed his residency and fellowships in internal medicine and nephrology. After receiving his PhD degree from Osaka University in 2005, he joined the faculty of the Department of Nephrology, Osaka University Graduate School of Medicine in 2007. He has been a member of the Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy since 2007. His main research interest focuses on the complications surrounding CKD, namely CKD-MBD and anemia. Due to his strong interest in cohort studies and having enrolled thousands of CKD patients, he moved to the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania in 2008, to be involved in the CRIC study, and worked for international collaboration studies between CKD cohorts in Japan and the US under the direction of Prof. Harold Feldman until 2012. He is currently affiliated to the Department of Comprehensive Kidney Disease Research (CKDR), Osaka University Graduate School of Medicine, for which he functioned as a co-founder.

Yutaka Harita



Yutaka Harita, MD graduated from Faculty of Medicine at Kyoto University and trained in Department of Pediatrics at the University of Tokyo and Department of Pediatric Nephrology at Tokyo Women's Medical University. As a pediatric nephrologist, his interests focus on pathogenesis of nephrotic syndrome. He received his PhD from the University of Tokyo and did his post-doctoral fellowship at Institute of Medical Science, the University of Tokyo (IMSUT) and Yokohama City University where he investigated the signaling networks in podocytes. Since 2011, he became a lecturer and a leader of Pediatric Nephrology at the University of Tokyo. More recently, his lab focused on the genetic background and humoral factors associated with proteinuria and nephrotic syndrome.

Kenichi Hongo



Professor, Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine
Graduated from The Jikei University School of Medicine, 3/1986
Medical Intern, The Jikei University School of Medicine, 4/1986-3/1988
Ph.D. Student, Department of Physiology, The Jikei University School of Medicine, 4/1988-11/1991
Resident, Department of Internal Medicine IV, The Jikei University School of Medicine, 12/1991-12/1992, 8/1995-12/1996
Post Doctoral Research Fellow, Department of Physiology, University of Leeds, UK, 1/1993-7/1995
Assistant Professor, Department of Internal Medicine IV, The Jikei University School of Medicine, 1/1997-12/2000
Assistant Professor, Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, 1/2001-1/2007
Associate Professor, Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, 2/2007-1/2014
Professor, Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, 2/2014-

Daijo Inaguma



Daijo Inaguma became professor of nephrology at Fujita Health University in July 2017. Daijo graduated from Nagoya University in 1988. Then, he worked as a clinician at Tosei General Hospital, Nagoya University Hospital, Japanese Red Cross Nagoya Daini Hospital and researched CKD-MBD, especially at pre-dialysis stage. He conducted a prospective cohort study named the AICOPP from 2011 to 2016, which was aimed to clarify a relationship between pre-dialysis management and prognosis after the initiation of dialysis in patients with chronic kidney disease. Approximately half of the patients (n=1,520) of initiated dialysis in Aichi prefecture in Japan were registered. Daijo and colleagues have shown that many factors including the decline of eGFR, heart rate, cancer baring, and combination therapy VDRA and renin angiotensin system blockers during pre-dialysis stage were associated with cardiovascular events and mortality. The AICOPP resulted in 13 publications in October 2017. In addition, Daijo conducted and started a new cohort study focusing on dialysis patients with aortic stenosis (AS) from July 2017. More than 1,000 patients with or without AS already registered in October 2017. Daijo and colleagues hope to provide information from the study in the future.



Tsuyoshi Inoue



Tsuyoshi Inoue is a research associate in the Division of Nephrology at the University of Virginia, USA. He received his PhD in Medicine from the University of Tokyo, Japan and received his MD from Nagasaki University, Japan. His recent publications include 'C1 neurons mediate a stress-induced anti-inflammatory reflex in mice (Nat Neurosci 2017)' and 'Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through $\alpha 7$ nAChR+ splenocytes (J Clin Invest 2016)'. His research interests include the neuro-immune interaction in acute kidney injury and the role of epigenetics in renal fibrosis.

Yoshitaka Isaka



Dr. Yoshitaka Isaka M.D. is a graduate of Osaka University Graduate School of Medicine, Osaka, Japan (1988) and trained at Osaka University Hospital and Osaka National Hospital (1988-1989). He was awarded a Ph.D. from Osaka University, and studied at University of Utah, Division of Nephrology and Hypertension (Prof. W.A. Border) as postdoctoral fellow. He became a professor at Osaka University (Department of Nephrology) in 2015. He was a board member of the Japanese Society for Dialysis Therapy, and committee secretary of the Japanese Society of Nephrology. He has been acting as an editorial board member of the Nephrology, Dialysis and Transplantation, PLOS ONE, Sci Rep, and Renal Replacement Therapy.

Tamara Isakova



Tamara Isakova, MD, MMSc is Associate Professor of Medicine in the Division of Nephrology and Hypertension at the Northwestern University Feinberg School of Medicine and Director of the Center for Translational Metabolism and Health within the Institute for Public Health and Medicine. She is a graduate of the State University of New York Downstate College of Medicine, and she completed internal medicine training at the Massachusetts General Hospital and nephrology training at the combined Massachusetts General Hospital and Brigham & Women's Hospital nephrology fellowship program. Dr. Isakova conducts clinical research in the area of disordered mineral metabolism in chronic kidney disease. She has received research support from the American Kidney Fund, the American Heart Association, the American Society of Nephrology, and the National Institute of Health. Dr. Isakova provides clinical care for patients with chronic kidney disease, bone and mineral metabolism disorders, and kidney stones.



Vivekanand Jha



Professor Vivekanand Jha is the Executive Director of the George Institute India, Professor of Nephrology at the University of Oxford, UK and the President-Elect of the International Society of Nephrology.

With a substantial research track record, Prof Jha is recognized as a global expert on kidney disease, especially from the point of view of low-middle income countries. He currently leads research projects operating in more than 20 countries worldwide. He is a member of Task Forces and Scientific Advisory Committees of the Department of Science and Technology of Government of India and is an Advisor to the World Health Organization (WHO).

Prof Jha has had leadership roles in the ISN, the Transplantation Society and International Society of Peritoneal Dialysis, and is the chair of the Asian Renal Consortium. He has written over 250 journal articles, 40 book chapters and is on the Editorial Board of several international journals.

David Johnson



Professor David Johnson is currently Director of the Metro South and Ipswich Nephrology and Transplant Service (MINTS) and Medical Director of the Queensland Renal Transplant Service at Princess Alexandra Hospital, Brisbane, Australia. He is President-elect of the International Society for Peritoneal Dialysis (ISPD), an International Society of Nephrology (ISN) councillor, Chair of the KHA-CARI Guidelines on Early CKD and Evaluation of Renal Function, Chair of the Primary Education Advisory Committee to Kidney Health Australia (PEAK-formerly KCAT), Chair of the Australasian Creatinine Consensus Group and Chair of the Global Kidney Health Atlas project. He has published over 750 original manuscripts in peer-reviewed journals, presented over 440 abstracts at national and international scientific meetings, delivered over 100 invited plenary and keynote lectures at international scientific meetings, led numerous large multi-center randomised trials (including IDEAL, HONEYPOT, CKD-FIX and balANZ), and received numerous national and international awards for his contributions to nephrology.


Takashi Kadowaki



Takashi Kadowaki is currently Professor and Chairman of the Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, at the University of Tokyo. He served as Director of the University of Tokyo Hospital and is the Chairman of the Board of Directors of The Japan Diabetes Society. His major research interests include molecular basis of insulin resistance and type 2 diabetes and he identified adiponectin receptors, Adipo R1 and Adipo R2. He has authored more than 600 original articles and reviews. He was the principal investigator of J-DOIT3: a multifactorial intervention trial for prevention of macrovascular complications and mortality. He served as an Associate Editor of *Diabetologia*. He also served as an editorial board member of *Diabetes*, *Diabetes Care* and *Journal of Clinical Investigation* and currently is on the editorial board of *Cell Metabolism* and *Molecular Metabolism*.



Keizo Kanasaki




Dr. Keizo Kanasaki is Associate Professor in the Department of Diabetology & Endocrinology, Kanazawa Medical University, Japan (2015~current). He graduated from Shiga University of Medical Science (MD and PhD). He carried out his post-doctoral training under the instruction of Professor Raghu Kaluri at the Department of Matrix Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston. His research and clinical interests are diabetic nephropathy and preeclampsia. He published the first genetic model of preeclampsia in Nature. These genetic defects in humans were found to be relevant in preeclampsia patients from many countries. Also he has been focused on the kidney fibrosis associated with endothelial or epithelial to mesenchymal transition program and their relevance. He is the award winner of Young Investigator Award from the Japan Society of Diabetic Complications, and Lilly Award from the Japan Diabetic Society for his diabetic nephropathy research.

Akihiko Kato



Akihiko Kato, MD is Professor at Blood Purification Unit of Hamamatsu University Hospital in Japan. He graduated from Hamamatsu University School of Medicine in 1985. He performed his nephrology fellowship in Hamamatsu University School of Medicine. From 1995 to 1997, he was a research fellow at Division of Nephrology of Emory University of Medicine with Prof. Mitch WE and Prof. Sands JM. His main work is to explore the association of inflammation with malnutrition and arteriosclerosis in dialysis patients. He also studied the changes of body composition, especially skeletal muscle and abdominal adipose tissue. He received Society Award of Japanese Society for Dialysis Therapy in 2005. He became Associate Professor of Blood Purification Unit at Hamamatsu University Hospital, and has worked as Professor since 2012. He is also interested in acute kidney injury (AKI), and examines the role of cell cycle dysregulation, oxidative stress and vasoactive substances using several AKI models.

Junichiro James Kazama



Education

1979	Graduate from Bay High School, Bay Village OH, USA
1981	Graduate from Niigata-Daiichi High School, Niigata, Japan
1987	M.D. at Niigata University School of Medicine
1995	Ph.D. in Nephrology at Niigata University Graduate School of Medicine

History of Professional and/or Academic Position

2002-2009	Clinical Assistant Professor, Division of Intensive Care Medicine, Niigata University Medical and Dental Hospital
2009-2010	Associate Professor, Advanced Critical Care and Disaster Rescue Medical Center, Niigata University Medical and Dental Hospital
2010-2016	Associate Professor and Director, Division of Blood Purification Therapy, Niigata University Medical and Dental Hospital
2016-present	Professor and Director, Department of Nephrology and Hypertension, Fukushima Medical University




Yon Su Kim




Professor Kim trained as an internist at Seoul National University Hospital. After training, he joined Professor Terry Strom's laboratory at Harvard Medical School, Beth Israel Deaconess Medical Center as a fellow. He has held a faculty position since 1999 and was promoted to professor in 2012. Currently, he serves as a vice president of the Seoul national University Hospital and will serve as a president of Korean Society of Nephrology from 2018. His research interests focus on kidney transplantation and chronic kidney disease. He published more than 100 SCI papers and led a team focusing on basic science as well as translational research.

Hirotaka Komaba



Hirotaka Komaba is junior associate professor of the Division of Nephrology, Endocrinology and Metabolism at Tokai University School of Medicine. He received his MD from Kobe University School of Medicine, and completed his PhD at Kobe University Graduate School of Medicine, where he was trained under the mentorship of Dr. Fukagawa. Following a transfer to Tokai University School of Medicine, he spent two years in the Division of Bone and Mineral Research at Harvard School of Dental Medicine, where Dr. Lanske supervised his research. His primary research focuses on disordered mineral metabolism and FGF23-Klotho axis in CKD. He has authored more than 60 original articles and reviews including in *KI*, *CJASN*, *AJKD*, *NDT*, *JCEM*, *Nature Reviews Nephrology*, and *Cell Metabolism*. He has served as a member of the 2012 CKD-MBD Guideline Working Group of the Japanese Society for Dialysis Therapy.

Joel D. Kopple



Joel D. Kopple, M.D. is Professor of Medicine and Public Health at the David Geffen School of Medicine at UCLA and the UCLA Fielding School of Public Health and was Chief of the Division of Nephrology and Hypertension at Harbor-UCLA Medical Center for 25 years. Dr. Kopple's research focuses on protein and amino acid metabolism in health and disease, skeletal muscle metabolism and physical exercise training, and the nutritional and metabolic disorders and their prevention and treatment in acute and chronic kidney disease and kidney failure. He has published research on the disorders of protein, energy, vitamin and mineral metabolism in kidney disease and kidney failure and the dietary requirements for protein energy, and many minerals and vitamins in these conditions. He has published approximately 550 peer reviewed manuscripts, book chapters and reviews, and edited or co-edited many proceedings as well as co-edited three editions of the book, "Nutritional Management of Renal Disease". His contributions have been recognized by many honors and awards including three honorary university doctorate degrees. He is a Past-President of the National Kidney Foundation, the American Society for Parenteral and Enteral Nutrition (ASPEN), the International Society for Renal Nutrition and Metabolism, the International Federation of Kidney Foundations and the Council of American Kidney Societies. Dr. Kopple has played a seminal role in founding the International Society for Renal Nutrition and Metabolism, The International Federation of Kidney Foundations, and World Kidney Day, and served a central role in founding the Rhoads Research Foundation of ASPEN and the National Kidney Disease Education Program (NKDEP) of the NIH. The National Kidney Foundation Council on Renal Nutrition has established the annual Joel D. Kopple Lectureship and Award, and The International Federation of Kidney Foundations has also established an annual Joel D. Kopple Award.



Noriko Koteda



Education

- graduated from the National University of Ureshino Hospital Nursing School in March, 1976

Affiliated academic society

- joined Chiba Nursing Association in April, 1985, leading to the present
- joined The Japanese Society for Dialysis Therapy in April, 1986, leading to the present
- joined Japan Academy of Nephrology Nursing in April, 1998, leading to the present

Achievement

- assumed a chief of Chiba Community Branch of Chiba Nursing Association, in May, 2007
- contributed to nursing activities in Chiba prefecture by planning and managing community activities via "the town nurse's room" of Chiba City In addition to the above
- acquired a qualification of Care Manager, Dialysis Technician Certification and Dialysis Leading Nurse with a wealth of experience and expertise for dialysis
- served as a director of Chiba Dialysis Study Group and Chiba kidney Failure Nursing Society
- served as a chairperson & a director of Dialysis Leading Nurses of The Society of Japan Kidney Failure
- became a member of Chiba City Nursing Certification Examination Committee in April, 2013
- managed The 17th Japan Academy of Nephrology Nursing Science Meeting as a chairperson in November, 2014
- appointed as a Chiba Branch head of Chiba Nursing Federation in April, 2016
- awarded Chiba Nursing Merit Award 2017

Robyn Langham



Professor Langham is Head of School of Rural Health at Monash University, a nephrologist and clinician researcher. She has a PhD in molecular analysis of human renal disease, and continues to work in fields of basic, translational and clinical renal research. Her work with Professor Kelly's team at the University of Melbourne resulted in the successful development of novel anti-fibrotic agents for use in renal and other chronic end-organ diseases. As a past President of the ANZSN, previous Chair of the Victorian Government Renal Health

Clinical Network, the past Secretary-General of the ISN, and through ongoing roles in contributing to the work of Kidney Health Australia, she is truly committed to improving the health outcomes of all people with kidney disease through innovative research and new models of care.



Philip Kam-Tao Li



Prof. Philip Kam-Tao Li is the Chief of Nephrology & Consultant Physician of the Department of Medicine and Therapeutics at the Prince of Wales Hospital (PWH), Hong Kong. He is also the Honorary Professor of Medicine at the Chinese University of Hong Kong. Prof. Li is the President of Asian Pacific Society of Nephrology and the Immediate Past President of International Society for Peritoneal Dialysis. He is also the President of the International Association of Chinese Nephrologists (IACN). He is the President of the Hong Kong College

of Physicians. He is the Chairman of the Central Renal Committee of Hospital Authority of Hong Kong. He is the Co-Chair of International Steering Committee for World Kidney Day.

Prof. Li was the Chairman of the Local Organizing Committee and Scientific Co-chair for the World Congress of Nephrology 2013. He was the President of the Organizing Committee for the 1st International Congress of Chinese Nephrologists 2015.

Prof. Li has been Visiting Professor to Nanjing University, Fudan University and Peking University, China, Nagoya University, Japan and Brown University, USA.

He has published over 510 original and review articles in peer-reviewed journals, four books and 20 book chapters. He has given over 180 lectures to international congresses, meetings and academic institutions.

Adrian Liew



Dr Adrian Liew is a Senior Consultant and Chief of Nephrology at the Department of Renal Medicine, Tan Tock Seng Hospital in Singapore. He is an Associate Professor of Medicine and is the Renal Curriculum Lead with the Lee Kong Chian School of Medicine at the Imperial College London-Nanyang Technological University. He serves in his professional capacity as a Senior Consultant with the Ministry of Health, Singapore, is the Chair of the National HALT-CKD Program, and is a member of various national advisory committees.

Dr Liew is an elected council member of the International Society of Nephrology, and has also been elected as a Fellow to various academic institutions including the Royal College of Physicians in the United Kingdom, American Society of Nephrology and the Academy of Medicine, Singapore. He is the National Leader for various multicentre clinical trials, and has research interests in glomerular diseases, renal immunology and peritoneal dialysis. He has also been actively involved in the training and development of renal programs in various countries in Southeast Asia and has provided sister renal center mentorship to nephrologists in several developing countries.

Ziad A. Massy



Ziad A. Massy is Professor of Nephrology and Head of the Division of Nephrology at the Paris West University (UVSQ)-Ambroise Paré University Hospital, Paris, and Co-Director of Research Unit INSERM U-1018 at the UVSQ, Versailles/Villejuif, France. Prof. Massy is a Member of ERA-EDTA Council and Chair for the ERA-EDTA Registry. He is a Core-member of the Executive KDIGO board, the EURECAM Working Group Advisory Board -ERA-EDTA, Core-member of the CKD-MBD WG Working Group Advisory Board, and a

current member and former co-chairman of European Uremic Toxins (EUTox) group. He obtained the Fondation du Rein award in September 2010 and the Hungarian Society of Nephrology award in November 2015. His research areas of special interest include cardiovascular disease, vascular calcification, hyperlipidemia, uremic toxins, oxidative stress, and chronic renal failure. He has published several original articles, reviews and chapters of books in his domain of interest (Index H: 52, Publications Medline total n=375).



Kunihiro Matsushita



Dr. Kunihiro Matsushita is Associate Professor of Epidemiology and Core Faculty of the Welch Center for Epidemiology, Prevention and Clinical Research. He is also the Director of the Data Coordinating Center of the Chronic Kidney Disease Prognosis Consortium (CKD-PC), an international consortium consisting of more than 80 cohorts from 40 countries. He is a certified cardiologist in Japan and has expertise in risk factors for cardiovascular disease (CVD), and in applying epidemiological methods to create an evidence base to improve the prevention and management of CVD and its risk factors such as hypertension, diabetes, and chronic kidney disease. In addition to CKD-PC, he is also investigating various data resources including research cohorts such as the Atherosclerosis Risk in Communities (ARIC) Study as well as data based on electronic medical records.


Orson W. Moe



Orson Moe received his medical degree from the University of Toronto and is currently Professor of Internal Medicine and Physiology at the University of Texas Southwestern Medical Center, USA. He is the Director of the Pak Center of Mineral Metabolism and Clinical Research, and Chief of the Nephrology Division at Southwestern, USA. Moe holds the Charles and Jane Pak Distinguished Chair in Mineral Metabolism Research and the Donald Seldin Professorship in Clinical Investigation.

Moe conducts both basic science and patient-oriented research on renal physiology and metabolism, and epithelial biology. He is editing *Current Opinion in Nephrology and Hypertension*, and the textbook *Seldin and Giebisch's The Kidney: Physiology and Pathophysiology*. He is currently a member of the American Society of Clinical Research, American Association of Physicians, American Society of Nephrology, International Society of Nephrology, and American Physiologic Society.

Naoki Nakagawa



Naoki Nakagawa, M.D., Ph.D. is the Assistant Professor of Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine at Asahikawa Medical University, Hokkaido, Japan.

He received his M.D. at Jichi Medical University and Ph.D. at Asahikawa Medical University and residency training at Asahikawa Medical University Hospital. Dr. Nakagawa is a physician scientist conducting basic and clinical research in nephrology and hypertension. His basic research area is oxidative stress and prostanoids in the pathophysiology of kidney fibrosis. His clinical research area is the pathophysiology of cerebro-cardio-renal continuum in patients with chronic kidney disease. He has an interest in screening and initiating early therapy for patients with Fabry disease.

Dr. Nakagawa is the elected member of the Academic Committee of the Japanese Society of Hypertension since 2016.

Daisuke Nakano



Daisuke Nakano, PhD, is an Assistant Professor of Pharmacology at Kagawa University. Dr. Nakano received a PhD in pharmaceutical sciences in Osaka University of Pharmaceutical Sciences in 2006, and did his postdoc at Medical College of Georgia, where he started kidney research. Dr. Nakano imported an intravital imaging technique using multiphoton microscopy in 2010 through the collaboration with Dr. Janos Peti-Peterdi in University of Southern California. Dr. Nakano's team is developing a keen interest in the interaction among the tubule, interstitium, capillaries and fluid including urine, interstitial fluid and plasma.

Atsuko Nakatsuka



Dr. Atsuko Nakatsuka is the Assistant Professor of the Division of Kidney, Diabetes and Endocrine Diseases, Okayama University Hospital, Japan (2014-present). She obtained Ph.D. degree in Medicine from Okayama University Graduate School and had been serving as Assistant Professor of the Department of Diabetic Nephropathy, Okayama University Graduate School (2012-2014). Her research interests are directed to the molecular mechanisms of diverse complications of obesity and diabetes, especially in kidney, liver and fat tissues. She is currently dedicated to the investigation of the role of adipokines in diabetic kidney disease (DKD). She has been recognized with many of prestigious awards; Okayama Medical Association Award (Sunada Prize) (2014), The Japan Society of Diabetic Complications, Young Investigator Award and 28th Young Investigator Okamoto Award (2013), Okayama Medical Association Award (Yuuki Prize) and Academic Award of the Okayama Prefectural Medical Association (2012), KEYSTONE SYMPOSIA, Diabetes, Barrie Hesp Scholarship (2010), 43rd European Association for the Study of Diabetes, Travel Grant Award (2007).

Saori Nishio



Education

Asahikawa Medical College in Japan M.D. 1995
Hokkaido University in Japan Ph.D. 2004

Positions and Employment

1995-1996	Medical doctor, Department of Medicine, Hokkaido University Graduate School of Medicine
1996-2000	Medical doctor, Internal Medicine
2004-2005	Post doctoral fellow, Department of Medicine, Hokkaido University Graduate School of Medicine
2005-2007	Postdoctoral associate, Yale University School of Medicine
2007-2008	Post doctoral fellow, Department of Medicine, Hokkaido University Graduate School of Medicine
2008-2015	Assistant professor, Department of Medicine, Hokkaido University Graduate School of Medicine
2015-	Associate professor, Department of Medicine, Hokkaido University Graduate School of Medicine

Membership

Japanese Society of Internal Medicine (Board certified member)
Japanese Society of Nephrology (Board certified member)
Japanese Society of Dialysis Therapy (Board certified member)
Japanese Society for Clinical Renal Transplantation
American Society of Nephrology
International Society of Nephrology




Kandai Nozu



Dr. Nozu graduated from the faculty of medicine, Kobe University in 1996. After training in general pediatrics for four years, he received pediatric nephrology training at Kobe University Hospital. He got a Ph.D degree from Kobe University in 2005. He studied molecular biology in the division of pediatric nephrology at the Medical College of Wisconsin between 2010 and 2013. He received the Clinical Scientist award 2017 from the Japanese Society of Nephrology and three Young Investigators awards from the Japanese Society of Pediatric Nephrology. He is now the Associate Professor of Pediatrics, Kobe University Graduate School of Medicine, the chief of Pediatric Nephrology department in Kobe University Hospital and the director of the Lab in the department of Pediatrics, Kobe University. He is also a member of the American Society of Nephrology, International Pediatric Nephrology Association, Japanese Society of Nephrology, Japanese Society of Pediatrics, Japanese Society of Pediatric Nephrology.

Osamu Nureki



Osamu Nureki completed his education and gained a D.Sc. at the University of Tokyo (Graduate School of Science). After receiving the doctorate, he worked one year in RIKEN as a post-doc, and then worked as the assistant professor and associated professor at the University of Tokyo for eight years. In 2003, he became the full professor at Tokyo Institute of Technology, and continued the structural studies of translational apparatus, and also started the project of membrane protein. In 2008, he moved to the University of Tokyo (Institute of Medical Sciences), and mainly worked on membrane transporters and cancer research to design anti-cancer drugs. In 2010, he finally moved back to the University of Tokyo (Graduate School of Science). His group has three main research projects. 1. Membrane channels and transporters, 2. RNA silencing and CRISPR-Cas system, and 3. Chronic inflammation. Especially, his group has pioneered high-resolution crystallography of membrane proteins using lipidic cubic phase crystallization method and microfocus beam in SPring-8 synchrotron.

Yoshitsugu Obi



Dr. Obi studied medicine at Yamanashi Medical University in Japan and also obtained his PhD degree from Osaka University Graduate School of Medicine, Japan. He is a Fellow of the Japanese Society of Internal Medicine (FJSIM), a Japanese-board certified nephrologist/transplant physician, and a Fellow of the American Society of Nephrology (FASN). Since he joined Dr. Kalantar's research team at UC Irvine in September 2014, he has published over 20 papers with his name under the first author in several high-impact, peer-reviewed journals. Dr. Obi conducts research studies centered on residual kidney function and disorders of bone and mineral metabolism in chronic kidney disease. He also participates in prospective translational studies using urine samples from non-dialysis dependent CKD patients and kidney transplant recipients. He also serves as a Board member in *Cardiorenal Medicine* and *Renal Replacement Therapy*.

Kenji Osafune



Dr. Osafune graduated from Kyoto University, Japan in 1996, and completed his nephrology residency in Kyoto University Hospital and its affiliated hospitals. In 2000, he started basic research into kidney development and regeneration at The University of Tokyo (Prof. Makoto Asashima), then he worked on pancreatic regeneration using hESCs/iPSCs as a postdoctoral fellow with Prof. Douglas A. Melton at Harvard University, USA. He became Principal Investigator at the Center for iPS Cell Research and Application (CiRA), Kyoto University, in 2008. In 2014, he was appointed Professor at CiRA, Kyoto University. He is on the editorial board of *Differentiation* and *Nephron Experimental Nephrology*. He has published original articles in peer-reviewed international journals including *Nature Biotechnology*, *Nature Chemical Biology*, *Nature Communications*, *Cell*, *Cell Stem Cell* and *Science Translational Medicine*. His major research interests are the development of regenerative therapies against diabetes and chronic kidney disease and disease modelling for polycystic kidney disease.

Vlado Perkovic



Vlado Perkovic is Executive Director of The George Institute, Australia, Professor of Medicine at UNSW Sydney, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is on preventing the development and progression of kidney disease and its complications. He leads or serves on the Steering Committees of several major clinical trials, and is a Director of George Clinical, the clinical trials arm of The George Institute. He has contributed to Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management. Vlado is a member of the Australian National Health and Medical Research Council Principal Committee on Research Translation; is Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACT) group; and is a Fellow of the Royal Australasian College of Physicians, the Australian Academy of Health and Medical Sciences, and of the American Society of Nephrology.

Lisa Pettigrew



Lisa is the Global Industry Strategy Leader for DXC Technology's Enterprise & Cloud Applications (ECA) Group. Within DXC Technology, the ECA Group is the engine for digital growth housing most of the company's recent acquisitions. In this role, Lisa leads the development of the global industry vertical strategy focused on healthcare and financial services for the digital applications and services identifying market differentiations, value propositions supported by innovative commercial models and strategic partnerships. Lisa has previously held general manager roles in the Americas, Australia and Asia Pacific leading healthcare and life science businesses. Lisa was also formerly the Global Healthcare Strategy Leader for Healthcare. In 2013, Lisa was named one of the company's Ingenious Minds. In 2017, for the second year in a row, Lisa was named in Health Data Management's Most Powerful Women in Healthcare IT, in the Thought Leader category. Lisa lives in Washington DC.



Peter J. Ratcliffe



Peter Ratcliffe is Director of Clinical Research at the Francis Crick Institute, London, and Professor of Medicine at the University of Oxford. Peter trained as a nephrologist before founding the Hypoxia Biology Laboratory at Oxford, initially studying the regulation of erythropoietin by oxygen levels in the kidneys. His laboratory demonstrated that this system of oxygen regulated gene expression is widespread in animal cells and performs many other functions. His laboratory also elucidated the mechanism of oxygen sensing through the catalytic hydroxylation of specific amino acid residues in the transcription factor, Hypoxia Inducible Factor (HIF). The laboratory is currently engaged in the biochemical, physiological and therapeutic characterisation of this and related pathways. He has received several awards in recognition of this work, including the Louis-Jeantet Prize in Medicine, the Canada Gairdner International Award, and the Albert Lasker Basic Medical Research Award.

Yusuke Sakaguchi



Dr. Sakaguchi is an Assistant Professor of the Department of Comprehensive Kidney Disease Research at Osaka University, Japan. He received his M.D. from Osaka University in 2006. After he completed a fellowship in nephrology at Osaka General Medical Center, he studied geriatric medicine and nephrology at Osaka University Graduate School of Medicine from which he received his Ph.D. in 2015. His major research interest focuses on the role of magnesium on the phosphate toxicity in CKD. He has published both clinical and experimental data which suggested the benefit of increasing magnesium levels of CKD patients for improving their prognosis. He is currently conducting several ongoing randomized controlled trials to explore the clinical usefulness of magnesium supplementation for CKD patients.

Hisamitsu Sato



Hisamitsu Sato began his career in 1983, working at the Masuko Memorial Hospital. In 1987, he acquired his nursing license and enrolled to the Japanese Academy of Nephrology Nursing (JANN) in 1999. He became chief director of JANN in October 2017.

Minoru Satoh



Minoru Satoh is Associate Professor of the Department of Nephrology and Hypertension at Kawasaki Medical School, Okayama, Japan. After he graduated the Okayama University Medical School in 1993, he trained at Kobe West City Hospital and Iyomishima Hospital. He received his PhD from Okayama University Graduate School of Medicine and Dentistry in 2001. He spent from 2004 to 2006 as a post-doctoral fellow involved in vascular medicine research at Brigham and Women's Hospital, Harvard Medical School. Since 2006, he has worked at Kawasaki Medical School, and was assigned his current position in 2014. Dr. Satoh's major research interest is in hypertension and nephropathy. He is especially interested in vascular complications and endothelial dysfunction in these areas with particular focus on oxidative stress.

Toshihiro Sawai



Toshihiro Sawai is an Associate Professor of Shiga University of Medical Science in Japan and works as the section head for pediatric nephrology. He received his clinical training as a 'pediatric nephrologist' at Tokyo Women's Medical University. Dr. Sawai is a board-certified senior pediatrician, nephrologist, and clinical geneticist. For about ten years, Toshihiro Sawai has had an interest in the study of diagnostic techniques for complement-related renal diseases in children. He treated his first patient with atypical hemolytic uremic syndrome (aHUS) in 2008. Since then, he has worked on the study of complement-mediated renal diseases such as aHUS and C3 glomerulopathy. In 2015, Toshihiro Sawai studied analytical techniques on the complement system at the Centro de Investigaciones Biológicas in Madrid, Spain under Dr. Rodríguez de Córdoba.

Hiroko Segawa



Hiroko Segawa is an associate professor of the Department of Molecular Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School. Dr. Segawa received her BSc, MSc and PhD (Nutrition) from Tokushima University School of Medicine. She started her career as a scientist at Tokushima University as research fellow for young scientist of the Japan Society for the Promotion of Science (1999) and as Assistant Professor of Department of Molecular Nutrition (2000). After she spent two years as visiting scientist at the endocrine unit (Dr. Jueppner Lab.), Massachusetts General Hospital, Boston (2008-2010), she was promoted to Associate Professor of Tokushima University Graduate School (2010). Her research focuses on nutrient transporters such as amino acids, peptides and phosphate (Pi) and their regulation mechanism in the body. Her present primary research is molecular characterization, regulation, and genetic disease related to Pi homeostasis.



Christine B. Sethna



Christine Sethna, MD, EdM, is the Division Director of pediatric nephrology in the Department of Pediatrics at Cohen Children's Medical Center of New York. Dr. Sethna earned a Bachelors of Arts from Tufts University, a Masters of Education from the Harvard Graduate School of Education and a Doctorate of Medicine from SUNY Downstate School of Medicine. She completed her post-graduate training in general pediatrics and pediatric nephrology at The Children's Hospital of Philadelphia. As part of her fellowship training, she received

a professional Certificate in Biostatistics and Epidemiology from the University of Pennsylvania.

Dr. Sethna's clinical and research interests focus on hypertension and cardiovascular outcomes in kidney disease, specifically in children with nephrotic syndrome and kidney transplants. She is the Principal Investigator of a multi-center study sponsored by the American Heart Association that is investigating cardiovascular risk factors in children with nephrotic syndrome. She also serves as local principal investigator for several multi-center trials of kidney diseases, including the NIH-sponsored NEPTUNE and CureGN studies on nephrotic syndrome. In addition, Dr. Sethna is the Director of Resident Scholarly Activity for the Graduate Medical Education program at CCMC and a member of the Hofstra Northwell School of Medicine Admissions Committee. Dr. Sethna is an active member of numerous professional and scientific societies, including the American Society of Pediatric Nephrology, American Society of Nephrology and Society for Pediatric Research. She was the former section editor of nephrology for AAP Grand Rounds and is the current section editor for Frontiers in Pediatric Nephrology.

Catherine M. Shanahan



Professor Shanahan was educated in Australia and obtained a PhD in Genetics from the University of Adelaide. She began research in the field of cardiovascular medicine in the Biochemistry Department at the University of Cambridge UK. From 1995 to 2004 she was a British Heart Foundation (BHF) Lecturer and in 2005 became a BHF Senior Fellow in the Department of Medicine, University of Cambridge. In 2007 she left Cambridge to take up the Chair of Cellular Signalling in the Cardiovascular Division at King's College London

(KCL).

Professor Shanahan's work focuses on mechanisms of vascular smooth muscle cell (VSMC) dysfunction in ageing and disease and in particular the factors that promote accelerated calcification in children on dialysis.

She is a member of the British Atherosclerosis Society, British Society of Cardiovascular Research and North America Vascular Biology Organisation and serves on the Editorial Boards of Circulation Research and Arteriosclerosis, Thrombosis and Vascular Biology. She plays an active role in Athena Swan at KCL, an initiative to improve the participation and work experience of women in science.

Shigeru Shibata



Dr. Shigeru Shibata is Associate Professor of the Department of Internal Medicine, Teikyo University School of Medicine, and is Project Lecturer at the Research Center for Advanced Science and Technology (RCAST), the University of Tokyo. Dr. Shibata received his MD from the University of Tokyo in 1999, and finished his four-year residency at Toranomon Hospital and Showa General Hospital. After he obtained his PhD at the University of Tokyo Graduate School of Medicine in 2007, Dr. Shibata worked as an associate research scientist in the Department of Genetics at Yale University School of Medicine, Connecticut, USA (Professor Richard P. Lifton lab), where he contributed to the series of discoveries on novel mechanisms and pathways at the downstream of renin angiotensin aldosterone signaling in the kidney. His research interests include hypertension, electrolyte homeostasis, and chronic kidney disease.



Rukshana Shroff



Rukshana Shroff, MD, FRCPCH, PhD, is a Consultant in pediatric nephrology at Great Ormond Street Hospital for Children in London UK, and holds an academic position in nephrology (Associate Professor) at University College London. Her research focuses on cardiovascular disease in childhood chronic kidney disease (CKD), including laboratory work, clinical research studies and clinical trials. She is the PI on a multicenter study comparing long-term outcomes of conventional hemodialysis and hemodiafiltration in children. She currently holds a prestigious senior fellowship from the National Institute for Health Research (NIHR) to continue research into mineral dysregulation in CKD. She has published more than 130 original articles, reviews and book chapters in the fields of nephrology and dialysis. Dr Shroff has served on the recent KDIGO CKD-MBD guideline update group and two guideline committees for the National Institute for Health and Care Excellence (NICE). She is on the Council for the European Society for Pediatric Nephrology. She is currently an Associate Editor for Pediatric Nephrology and serves on the editorial board of the Clinical Journal of the American Society of Nephrology.

Tadashi Sofue



Tadashi Sofue, MD, PhD, is a Division Director of Nephrology and Dialysis Unit, Department of CardioRenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Japan. His recent research interests include marginal donor and recurrent glomerulonephritis in living-donor kidney transplantation.

Paweena Susantitaphong



Dr. Paweena Susantitaphong received her medical degree (with First Class Honors) from Chulalongkorn University in 2002. She trained in Internal Medicine at Khon Kaen University in Thailand, and later specialized in Clinical Nephrology at the Chulalongkorn University. She was also a visiting fellow at University Hospital Ghent in Belgium. She received the International Society of Nephrology COMGAN Fellowship Award in 2011-2012. She recently completed a Clinical Research Fellowship at St. Elizabeth's Medical Center, Tufts University School of Medicine in Boston, Massachusetts, USA and she has been an adjunct associate professor at Tufts University School of Medicine, Boston, USA. Dr. Susantitaphong's major research interests include hemodialysis and chronic kidney disease-mineral and bone disease. She is also interested in carrying out evidence-based medicine analysis especially systematic review and meta-analysis.

Dr. Susantitaphong has contributed to more than 30 chapters in medical textbooks, and has published over 50 articles in various regional and international peer-reviewed journals. She is an ad-hoc reviewer for several scientific journals such as Kidney International, American Journal of Kidney Diseases, Nephrology Dialysis Transplantation. She has had several oral and poster presentations and is also regularly invited as a speaker in national and international medical meetings and conferences.



Tetsuhiro Tanaka



Tetsuhiro Tanaka is a current employee at the Division of Nephrology and Endocrinology, the University of Tokyo School of Medicine. His major research interest is the role of chronic hypoxia and hypoxia-inducible gene transcription in the pathogenesis of CKD. He graduated from the University of Tokyo School of Medicine in 1997 and obtained his PhD degree at the University of Tokyo Graduate School of Medicine in 2005. He received the Young Investigator Award of the Japanese Society of Nephrology in 2014. He is currently serving as an editorial board member of *Kidney International* and *Clinical and Experimental Nephrology*.

Sydney C.W. Tang



Sydney Tang graduated from the University of Hong Kong and has obtained MD and PhD degrees at the University of Hong Kong. He has undergone training in basic science research in nephrology at Guy's Hospital, King's College London, and Seattle Children's Hospital, University of Washington. He is currently Chair Professor of Renal Medicine and *Yu Endowed Professor in Nephrology* at The University of Hong Kong. His research interests range from basic to clinical sciences including the role of renal tubular cells in diabetic and proteinuric nephropathies, and the treatment of IgA nephropathy. He has published over 200 journal articles and 25 textbook chapters, edited one book, and is on the Editorial Boards of a number of nephrology journals including *KI*, *CJASN*, *NDT*, *American Journal of Nephrology*, *Nephrology*, and *Journal of Nephrology*. He serves the Hong Kong College of Physicians as Chairman for Basic Training, and the Royal College of Physicians of Edinburgh as International Advisor. He is currently Chairman of the Hong Kong Society of Nephrology, Executive member of the Asian Pacific Society of Nephrology, and the North and East Asia Regional Board of the International Society of Nephrology. He is also on the Meetings Committee of the International Society of Nephrology. He has been invited to deliver lectures at many national and international meetings including the American Society of Nephrology Kidney Week and the World Congress of Nephrology. He is also a Subtheme Co-chair of the Scientific Committee of the Asian Pacific Congress of Nephrology to be held in Beijing.

Ravi Thadhani



Ravi Thadhani, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School, Chief of the Division of Nephrology at Massachusetts General Hospital, and Executive Director of the Clinical Trials Office at Partners Health Care. He received his Doctor of Medicine degree from the University of Pennsylvania in 1991, and, in 1997, received his Masters in Public Health in Epidemiology from the Harvard School of Public Health.

He is a clinical and translational investigator and, over the past 16 years, his research laboratory (<http://thadhanilab.org/>) has focused on understanding vitamin D metabolism and medical complications of pregnancy (preeclampsia and gestational diabetes). He has performed observational studies, collaborated with basic scientists in animal experimental studies, and translated these findings to multinational randomized trials to test several hypotheses in humans. More recently, he and collaborators put forward another paradigm-changing concept related to bioavailable vitamin D, potentially changing our view of who truly is vitamin D deficient.



Marcello Tonelli



Dr. Marcello Tonelli is Senior Associate Dean (Clinical Research) at the Cumming School of Medicine and Associate Vice President (Health Research) at the University of Calgary. He is a nephrologist and Professor at the University of Calgary. Dr. Tonelli is the past President of the Canadian Society of Nephrology, a former Councillor of the International Society of Nephrology, and the chair of the International Society of Nephrology Research Committee.

Katherine R. Tuttle



Katherine R. Tuttle, MD, FASN, FACP, FNKF is the Executive Director for Research at Providence Health Care in Spokane, Washington. Dr. Tuttle serves the University of Washington as a Co-Principal Investigator of the Institute of Translational Health Sciences, established Investigator at the Kidney Research Institute, and Clinical Professor of Medicine. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas. Dr. Tuttle is a member of the Board of Directors for the Kidney Health Initiative. She was Associate Editor for the *Clinical Journal of the American Society of Nephrology* from 2011-2016. She chaired the Healthcare Professional Workgroup for the National Diabetes Education Program (2006-2011), the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative Workgroup for Diabetes and Chronic Kidney Disease (2004-2012), the Institutional Review Board-Spokane (1999-2012), the Diabetes and Chronic Kidney Disease Consensus Conference for the American Diabetes Association (2014), and the National Kidney Foundation Young Investigator Awards (2014). She has received the Garabed Eknayan Award from the National Kidney Foundation (2017), the YWCA Woman of Achievement Award in Science (2009), and two Outstanding Clinical Faculty Awards at the University of Washington (1992, 2012). Dr. Tuttle holds fellowships in the American College of Physicians, the American Society of Nephrology, and the National Kidney Foundation. Her major professional interests are diabetic kidney disease, hypertension, and chronic kidney disease.




Shu Wakino



Graduate from Keio University in 1990.
Research fellow in University California in Los Angeles from 1999 to 2001
Resident doctor in the Division of Nephrology, Endocrinology and Metabolism
in the Department of Medicine, Keio University
Assistant Professor in Keio University in 2010
Associate Professor in Keio University in 2015

Angela Yee-Moon Wang



Angela Yee-Moon Wang, MD, PhD, FRCP, is an Honorary Associate
Professor at the University of Hong Kong, Hong Kong.
She is the recipient of the National Kidney Foundation Joel D. Kopple Award in
2018 and received the International Society of Peritoneal Dialysis' John Maher
award in 2006, and the Travelling Lecturer award of Asian and Pacific Federa-
tion of Clinical Biochemistry in 2012.

She is the current President-Elect of the International Society of Renal Nutrition and Metabolism (ISRNM), executive committee member of KDIGO (January 2015-December 2017), ISN North and East Asia Regional Board member, committee member of the ISN-Advancing Clinical Trial Core Group, council member of the ISPD, executive committee member of the SONG Initiative and a workgroup member of the SONG-PD and SONG-HD CVD.

She is a current workgroup member of KDOQI Nutrition Guidelines in CKD (to be published in 2018) and the ISPD PD Adequacy Guideline update 2017. She has previously chaired the ISPD Adult Cardiovascular and Metabolic Guidelines (2012-2015) and is a Subcommittee Chair of the ISPD PDOPPS. She was also a core workgroup member of the first KDIGO - CKD-MBD guidelines (2007-2009).

She currently serves on the editorial board of several nephrology journals: Journal of the American Society of Nephrology (JASN), Clinical Journal of the American Society of Nephrology (CJASN), Nephrology Dialysis Transplantation (NDT) (Editor of Cardiovascular Section), BMC Nephrology (Associate Editor), American Journal of Nephrology, Nephron Clinical Practice (Associate Editor), Nephrology (Subject Editor), Journal of Renal Nutrition, Journal of Diabetes, Blood Purification, Bio-medicine Hub, etc. She was also previously Associate Editor of American Journal of Kidney Diseases (AJKD) and an International Editor of CJASN.

Her research interests are mainly focused on cardiovascular disease, vascular calcification and CKD-MBD, diet and nutrition in CKD and PD and residual kidney function in PD.



Christoph Wanner



Prof. Dr. Christoph Wanner is a Professor of Medicine and Head of the Division of Nephrology in the Department of Medicine at the University Hospital of Würzburg. He is a permanent Visiting Professor at the Charles University in Prague.

He has served as an Executive Committee member of Kidney Disease Improving Global Outcomes (KDIGO), the Renal Registry Chairman of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), an International Steering Committee member of the Residual Risk Reduction Initiative (R3i), and is an Advisory Board member of the European Renal Best Practice (ERBP).

He has published more than 600 scientific papers and articles on chronic kidney disease, dialysis treatment, dyslipidemia and cardiovascular diseases, diabetic kidney disease and outcomes as well as Fabry's disease.

Masayuki Yamamoto



Masayuki Yamamoto graduated from Tohoku University School of Medicine (1979) and Graduate School of Medicine (1983). Yamamoto was a postdoctoral fellow at Northwestern University (1983-1986) with Professor Doug Engel, and conclusively proved the presence of erythroid isozymes in heme biosynthetic enzymes. In 1989, Yamamoto revisited the Engel laboratory and in collaboration identified the GATA family of transcription factors. Yamamoto returned to Japan (1991) and started analyses on the regulation of *Gata1* and

Gata2 genes during hematopoiesis. He clarified the unique structure of the genes, and developed the notion *GATA-related leukemia*. Yamamoto became a Professor at the University of Tsukuba (1995) and started a series of analyses on CNC and Maf family of transcription factors. He identified the KEAP1-NRF2 system regulating the cellular response against electrophilic and oxidative stresses. In 2007, he returned to Tohoku University, and he continued to address many questions related to this important regulatory pathway.

Yoko Yoshida



Yoko Yoshida, Ph.D. is a researcher of the Tokyo University Hospital. She originally studied nutritional science at Nara Women's University, and underwent her postgraduate degree at Nara Medical University and received her Ph.D. from the department of Blood Transfusion Medicine. She is now working as a researcher in the Division of Nephrology and Endocrinology, University of Tokyo Hospital. Her main work is analyzing the patients with atypical hemolytic uremic syndrome (aHUS), and elucidating the molecular pathology of this disease.

She started her work regarding aHUS at Nara Medical University in 2011. She has been involved in establishing the diagnostic system of aHUS in Japan, and revealed the clinical and genetic characteristics of this disease ever since.



Xueqing Yu



Xueqing Yu graduated from Sun Yat-sen University of Medical Sciences in 1984 and received his PhD in 1996 from Department of Nephrology, Sun Yat-sen University and then spent a year at Monash Medical Centre in Australia for post-doc. Now Professor of Medicine and Director of Sun Yat-sen University's Institute of Nephrology, he's also the Vice Chancellor of Guangdong Medical University and President of the Chinese Society of Nephrology. He also serves as the Executive member of Asian Pacific Society of Nephrology and member of East Asian of COMGAN of ISN.

Yu's research interests range from the basic to clinical and translational research. Yu and colleagues have been studying the genetic underpinnings of IgA nephropathy in Han Chinese, and among other things, comparing them with Caucasian patients. Epidemiology looms large in Yu's portfolio as well. His group has been investigating the geographical variations of CKD prevalence; lifestyle (urban and rural), particular foodstuff, and even altitude seem to play a part. Besides his major epidemiological projects, Yu initiated a clutch of cohort studies, following up CKD and ESRD patients to figure out the risk factors that are important in influencing mortality in Chinese populations. Yu has undertaken 44 research grants, and published 443 papers in peer reviewed journals, including Nature Genetic, Nature Communication, Science Translational Medicine, Cell Metabolism, JASN, KI, etc.